Hyderabad biotech start-up PopVax launched its RNA Foundry on 31 October 2026, an integrated research, development and manufacturing facility for RNA medicines including personalised cancer vaccines.
PopVax plans to make more than 100 personalised cancer vaccine candidates in the next 12 months; each takes about 8-10 weeks and costs around USD 300,000.
Its AI platform reads a patient's tumour sequence to find neoantigens, then encodes them in an mRNA-lipid nanoparticle vaccine; the candidates are experimental, not approved treatments.
The facility, run with Stochastic Sciences, is built to global Good Manufacturing Practice (GMP) standards.
Tumour mutations create neoantigens — proteins found on cancer cells but not healthy ones. The vaccine's mRNA, carried in lipid nanoparticles, makes cells produce these proteins, training T-cells to hunt the tumour. mRNA works in the cytoplasm and never enters the nucleus or the genome.
Simple Analogy: A wanted poster printed for one specific criminal, not a general alert.
Hyderabad start-up developing mRNA vaccines and cancer immunotherapies; runs the RNA Foundry
National drug regulator; must approve clinical trials before any candidate reaches Indian patients
Parent law for the manufacture and approval of drugs and vaccines in India; GMP requirements flow from it.
Govern permission for clinical trials of new drugs and vaccines, which these experimental candidates would need.
GS Paper III > Science & Technology > Biotechnology, vaccines
General Awareness > Science & Technology
A protein made only by tumour cells because of their mutations — a target the immune system can tell apart from healthy tissue.
Fat-based carrier for mRNA; ionisable lipids turn positive in acidic endosomes and help release the payload into the cell.
Good Manufacturing Practice — quality standards for producing medicines.